Treace Medical Concepts to Present at Major Healthcare Investment Forums

MEVHunterX · 2025-12-31T09:08:36+00:00

Treace Medical Concepts will participate in the UBS Global Healthcare Conference on November 10 and the Stifel 2025 Healthcare Conference on November 11, 2025. They focus on innovative bunion correction solutions and invite investors to engage through webcasts.

MEVHunterX

2025-12-31 09:08:36

Abstract generation in progress

Treace Medical Concepts, Inc. (NASDAQ: TMCI), a pioneering medical technology firm specializing in innovative solutions for bunion and midfoot deformity correction, has confirmed its participation at two significant investor relations events scheduled for mid-November 2025.

Upcoming Conference Appearances

The company will present at the UBS Global Healthcare Conference on November 10, 2025, delivering a fireside chat session beginning at 11:45 am ET. The following day, November 11, 2025, Treace will be featured at the Stifel 2025 Healthcare Conference.

Investors and stakeholders interested in attending these presentations can access a live webcast and subsequent replay via the Treace Medical investor relations website at www.treace.com, where all materials will be made available for remote and on-demand viewing.

Company Overview and Market Position

Treace Medical represents a transformative force in surgical foot care, addressing a significant healthcare gap in the treatment of bunion deformities. The condition affects approximately 65 million Americans, with Treace estimating roughly 1.1 million suitable for surgical intervention annually.

The company’s flagship innovation, the Lapiplasty® 3D Bunion Correction® System, represents a patented breakthrough combining surgical instruments, implants, and proprietary techniques to address the three-dimensional nature of bunion deformities at their root cause—an unstable midfoot joint. This comprehensive approach enables patients to return to active lifestyles more effectively than traditional surgical methods.

Expanding Product Portfolio

Beyond its core offering, Treace has developed a comprehensive suite of solutions for diverse bunion presentations and surgical preferences. The Adductoplasty® Midfoot Correction System delivers reproducible surgical outcomes across various deformity classifications, while the SpeedMTP™ Rapid Compression Implant provides an alternative fusion-based approach for patients with specific anatomical considerations.

For surgeons seeking minimally invasive options, Treace offers the Nanoplasty™ 3D Minimally Invasive Bunion Correction System and Percuplasty™ Percutaneous 3D Bunion Correction System. The recently introduced SpeedPlate® Rapid Compression Implants extend the company’s fixation capabilities across multiple procedural applications beyond bunion correction.

Investor Relations and Additional Resources

For comprehensive information about Treace Medical’s technology platforms, clinical outcomes, and investor updates, stakeholders should visit www.treace.com regularly. The company maintains an active presence on professional networks including LinkedIn, X, Facebook, and Instagram.

For investor inquiries: Gilmartin Group, Philip Trip Taylor | IR@treace.net

For corporate inquiries: Mark L. Hair, Chief Financial Officer | mhair@treace.net | (904) 373-5940

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.